| Previous Close | 21.01 |
| Open | 20.94 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 800 |
| Day's Range | 20.63 - 21.42 |
| 52 Week Range | 7.76 - 24.24 |
| Volume | 249,108 |
| Avg. Volume | 604,464 |
| Market Cap | 777.514M |
| Beta (3Y Monthly) | 2.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CAMBRIDGE, Mass., April 15, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, granted restricted stock units and a non-qualified stock option to Robert Hesslein as inducements material to his entering an employment agreement with Voyager to serve as its general counsel. The inducement awards were approved by the Compensation Committee of Voyager’s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4) and became effective upon the commencement of Mr. Hesslein’s employment on April 1, 2019. Mr. Hesslein received a restricted stock unit award for 28,125 shares of Voyager common stock and a non-qualified stock option to purchase 168,750 shares of Voyager common stock.
CAMBRIDGE, Mass., April 02, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR) today announced the publication of interim results from the Phase 1b trial of VY-AADC, an investigational gene therapy treatment for Parkinson’s disease, in the peer-reviewed journal, Annals of Neurology. The publication titled “Magnetic Resonance Imaging-Guided Phase 1 Trial of Putaminal AADC Gene Therapy for Parkinson's Disease,” can be accessed online.
MRI Interventions, Inc. (MRIC) a platform neurosurgery company developing products designed to deliver navigation, ablation, deep brain stimulation, aspiration, biopsy and gene therapy today announced a collaboration with Voyager Therapeutics, Inc. (VYGR) to design, manufacture and supply the Variable Trajectory Array Guide, or V-TAG, neurosurgical device for Voyager. Under the collaboration, Voyager transferred its existing 510(k) clearance for the V-TAG device to MRI Interventions who will manufacture and supply the device as a choice for neurosurgeons, along with MRI’s Clearpoint® system, for use in Voyager’s RESTORE-1 Phase 2 trial of its VY-AADC gene therapy program for Parkinson’s disease. “We continue to evolve and expand our relationship with Voyager with the common goal of delivering gene therapy to specific regions of the brain with accuracy to give our patients the best possible chance at success,” commented Joe Burnett, President and CEO at MRI Interventions.
HENDERSON, NV / ACCESSWIRE / March 8, 2019 / The past few weeks have been busy with big bio taking over smaller biotechs developing novel therapies. Roche (RHHBY) said it would spend $4.8 billion in a ...
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Initiated RESTORE-1 Phase 2 trial for VY-AADC for Parkinson’s disease Began IND-enabling preclinical studies for ALS-SOD1 and Huntington’s disease programs Recently announced.
CORAL GABLES, FL/ ACCESSWIRE / February 22, 2019 / With the new year only a few months old, the biotech stock market is already whirring with the excitement surrounding companies developing nuanced approaches to creating a wide array of new forms of treatment options for patients in need of care. Naturally, companies in the biotech sector working to address these challenges are garnering significant notoriety among consumers as well as investors. Premier Health Group (PHGRF) (PHGI), Ocular Therapeutix Inc (OCUL), Voyager Therapeutics Inc (VYGR), and Amarin Corporation plc (NASDAQ:AMRN) represent 4 biotech stocks stepping up their game on Friday.
The delivery of sufficient quantities of antibodies across the blood-brain barrier is one of the major limitations of current biologic therapies for neurodegenerative diseases that require frequent systemic injections with large amounts of antibodies. Voyager’s vectorized antibody platform and approach aims to circumvent this limitation by delivering, with a potential one-time intravenous administration, the genes that encode for the production of therapeutic antibodies utilizing Voyager’s blood-brain barrier penetrant adeno-associated virus (AAV) capsids.
- Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein - Voyager to receive $65 million upfront and up to $245 million in preclinical and Phase ...
CAMBRIDGE, Mass., Feb. 19, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
CAMBRIDGE, Mass., Feb. 18, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
JERSEY CITY, N.J.-- -- Smart order routing technology connects to multiple exchanges and liquidity providers for access to more liquidity and better trade execution End-to-end solution enables trading with crypto wallet and custody solutions Advanced analytics, alerts, news feeds to research investments, monitor positions Instant funding and trading of 18 crypto assets with zero-commissions Voyager ...
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The ...
Collaboration leverages strengths and efforts of both companies towards developing and commercializing life-changing treatments for severe neurological diseases Neurocrine.
NEW YORK, Jan. 16, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the appointment of Omar Khwaja, M.D., Ph.D., as chief medical officer. Dr. Khwaja’s background includes extensive research, translational, and clinical therapeutic development experience in neuroscience, neurogenetics and rare disease in both industry and academic roles. Dr. Khwaja is joining Voyager from F. Hoffmann-La Roche AG (Roche) where he most recently served as Global Head of Neuroscience Translational Medicine and Global Head of Rare Diseases.
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced an update to its VY-AADC clinical program for Parkinson’s disease. In December 2018, the Company held a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss the overall development program for VY-AADC.
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced joining multiple partnerships with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) including the Parkinson’s Progression Markers Initiative (PPMI) and the Parkinson’s Disease Education Consortium (PDEC). “We are dedicated to finding a cure for Parkinson's disease and accelerating breakthroughs patients can feel in their everyday lives,” said Sohini Chowdhury, deputy chief executive officer of The Michael J. Fox Foundation.
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced dosing of the first patient in RESTORE-1, a Phase 2, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of VY-AADC for the treatment of Parkinson’s disease in patients with motor fluctuations that are refractory to medical management. “Patients with Parkinson’s disease need new therapeutic options, especially as the disease progresses and there is less AADC enzyme in parts of the brain where it is needed to convert levodopa to dopamine,” said Mark Richardson, M.D., Ph.D., Associate Professor, Director of Epilepsy and Movement Disorders Surgery at the University of Pittsburgh Medical Center and principal investigator in the RESTORE-1 trial.
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it has entered into collaborations with Brammer Bio (Brammer) and Fujifilm Diosynth Biotechnologies (Fujifilm) to further expand Voyager’s manufacturing capabilities to support the development of its gene therapy programs. The collaborations allow Voyager to transfer its state-of-the-art research and development production capabilities to best-in-class gene therapy contract development and manufacturing organizations (CDMO) with late-stage clinical and commercial-scale capabilities, particularly as it relates to the baculovirus/Sf9 system for manufacturing adeno-associated virus (AAV) gene therapies.
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
CAMBRIDGE, Mass., Nov. 19, 2018 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today reported its third quarter 2018 results, recent progress and corporate updates and will host a conference call and webcast today at 4:30 p.m. EST to discuss these results. “We made important progress advancing our innovative pipeline in the third quarter as we presented exciting new preclinical data with our Huntington’s disease and SOD1 ALS programs and today announced durable improvements in motor function at 18 months and beyond from the ongoing Phase 1b trial with VY-AADC in patients with Parkinson’s disease,” said Andre Turenne, president and chief executive officer of Voyager Therapeutics.